Business Wire

UVLrx™ European Launch: Targeting 14th Annual Aesthetic & Anti-Aging Medicine World Congress

Del

After a successful North American debut last month at the American Academy of Anti-Aging Medicine (A4M) in Las Vegas, UVLrx Therapeutics™ is pleased to announce the official European launch of its intravenous light therapy treatment system, the model UVL1500, at this year’s 14th Aesthetic & Anti-Aging Medicine World Congress (AMWC) from March 31st to April 2nd. Under the scientific supervision of the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM), the conference will attract over 10,000 physicians and researchers from more than 120 countries who are interested in the role of prevention in global aesthetic and anti-aging management. At the Congress, UVLrx Therapeutics™ will highlight the clinically proven benefits of light wavelengths utilized by its UVLrx™ Treatment System* for reducing inflammation, a key issue facing the entire $300 billion global industry today.

This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20160120006185/en/

The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A  ...

The UVLrx Station™ Model UVL1500 offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. Using the company’s patent-pending Dry Light Adapter™ and a standard IV catheter, the device treats blood intravenously, thus eliminating the need for removal of blood from the body. (Photo: Business Wire)

“Inflammation is a common side effect of all aesthetic procedures, whether they be facial laser treatments, injections or surgery,” said Michael Harter, CEO and president of UVLrx. “By immediately reducing inflammation caused by an aesthetic procedure, our technology will minimize pain and accelerate healing, which in turn will lead to better results and a more satisfied post-op patient.”

“Beyond aesthetic procedures, chronic inflammation can occur due to pathogens in the bloodstream and just everyday stress,” commented Rowland Hanson, chairman of UVLrx. “Left untreated, chronic inflammation accelerates the aging process and has been linked to heart disease, cancer and Alzheimer’s disease. This is why UVLrx is an essential adjunct therapy for physicians practicing both aesthetic and anti-aging medicine.”

In addition to its exhibitor booth at the Congress, UVLrx has secured an adjacent private salon for physician and distributor on-site demonstrations of its CE-marked UVLrx Station™ Model UVL1500. Moreover, UVLrx Chief Science Officer, Ryan Maloney, has been asked to speak at a special session at noon on Friday, April 1st, about the efficacy of ultraviolet light and UVLrx technology for both anti-aging and aesthetics purposes. To ensure that Congress attendees are aware of UVLrx Therapeutics’ participation at AMWC, the company has secured inside front cover advertising, as well as a two-page promotional article, in the March/April issue of PRIME Journal, which will be distributed to all Congress attendees as well as the publication’s nearly 100,000 additional print and online subscribers.

“We look forward to sharing our technology with the global aesthetics and anti-aging community at AMWC 2016 and demonstrating, in person, how the UVLrx Treatment System will benefit all physicians practicing in this field,” added UVLrx CSO Ryan Maloney. “We are especially excited that the theme of the Congress this year is prevention, given the clinically proven ability of the wavelengths utilized by the UVLrx Station™ to immediately reduce inflammation caused by such things as pathogens in the bloodstream, stress and a wide range of aesthetic surgical procedures.”

Ultraviolet blood irradiation (UBI) has been used for over a century to treat bacterial and viral infections and was awarded a Nobel Prize for treating lupus in 1903. Routinely used in hospitals around the world, this form of light therapy fell out of prominence in the U.S. with the advent of antibiotics in the 1950s. With the recent expansion of drug-resistant infections, blood irradiation offers significant advantages to pharmaceutical therapies. Furthermore, UVLrx’s intravenous system is superior to existing ultraviolet blood irradiation (UBI) in that it does not require removal of blood from the body.

To learn more, visit UVLrx.com and stop by the UVLrx Therapeutics booth (F18) at the Congress. Also be sure to attend the lecture “The Must of Detoxification” in Room Auric between 12:00 and 13:00 on Friday, April 1st, to hear from UVLrx Chief Scientist Ryan Maloney.

The UVLrx Station™ Model UVL1500 is not available for sale in the U.S.

* References to published specific wavelength studies available upon request.

About UVLrx Therapeutics

Based in Oldsmar, Florida, UVLrx Therapeutics is dedicated to evidence-based medicine in the field of light therapy and offers the first intravenous, concurrent delivery of ultraviolet-A (UVA) and multiple visible light wavelengths for treating a variety of medical indications. In addition to two Nobel Prizes and NASA-backed research, hundreds of international clinical trials have verified the health benefits of UV and other wavelengths of light utilized in the UVLrx™ Treatment System. For more information, please visit http://uvlrx.com.

About EuroMediCom (organizer of AMWC)

Based in Paris, France, EuroMediCom was co-founded by Catherine Decuyper and Christophe Luino. It is the official organizer of the Aesthetic & Anti-Aging Medicine World Congress (AMWC). This Congress has been launched with a strong belief that effective aging prevention and treatment must be comprehensively addressed integrating two aspects: using aesthetics strategy (dermatology and surgery) for the external appearance, and applying anti-aging medicine for internal well-being. EuroMediCom is not only present in Europe but also partner of many other major congresses in the rest of the world. Since the development of anti-aging medicine, EuroMediCom took an important part in the creation of the first world premier European University Master Program in Preventive, Regenerative and Anti-aging Medicine, recognized today as the best program in the field with an official delivered master degree by the Dresden International University. For more information, please visit http://v1.euromedicom.com/amwc-2016/index.html.

About the World Society of Interdisciplinary Anti-Aging Medicine (WOSIAM)

Based in Paris, France, the World Society of Interdisciplinary Aesthetic and Anti-Aging Medicine (WOSIAM) has quickly become the world's fastest growing anti-aging medicine society to federate international physicians and scientific societies. The main goal of this nonprofit organization is to promote anti-aging medicine through research and educational events for physicians and the general public. The society is predominantly formed by and for physicians. It is the belief of the society's board of directors that the best way for anti-aging medicine to advance is by the endorsement of medical doctors competent in administering safe, evidenced-based anti-aging therapeutics. For more information, please visit http://www.wosiam.org.

About the American Academy of Anti-Aging Medicine (A4M)

Based in Boca Raton, Florida, A4M is a leading nonprofit medical society dedicated to the detection, prevention and treatment of age-related diseases. Dedicated to educating physicians, scientists and the public on biomedical sciences, breaking technologies and preventative medicine issues, the A4M is comprised of over 26,000 members from 120 nations worldwide, including healthcare practitioners, scientists, researchers and governmental officials. For more information, see http://www.a4m.com.

Contact information

Press Contact:
Crier Communications
JP Lincoln, President
jp@crierpr.com
310-274-1072 x201
or
Business Contact:
UVLrx Therapeutics
Rowland Hanson, Chairman
Rowland@UVLrx.com

Om Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Følg saker fra Business Wire

Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.

Siste saker fra Business Wire

Calvin Klein, Inc. Announces the Spring/Summer 2018 Calvin Klein Underwear and Calvin Klein Jeans Global Advertising Campaign22.1.2018 14:00Pressemelding

Calvin Klein, Inc., a wholly owned subsidiary of PVH Corp. [NYSE:PVH], today announced its new CALVIN KLEIN UNDERWEAR and CALVIN KLEIN JEANS global multi-media advertising campaign. The campaign represents the latest iteration of the evolution in the CALVIN KLEIN brand’s globally recognized #MYCALVINS call to action: Our Family. #MYCALVINS. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005732/en/ CALVIN KLEIN, INC. ANNOUNCES THE SPRING/SUMMER 2018 Campaign Led by Kim Kardashian West, Khloé Kardashian, Kourtney Kardashian, Kendall Jenner and Kylie Jenner Shot by photographer Willy Vanderperre, the latest chapter of this new campaign features sisters Kim Kardashian West, Khloé Kardashian, Kourtney Kardashian, Kendall Jenner and Kylie Jenner. The siblings are featured wearing styles of CALVIN KLEIN UNDERWEAR that are available in stores and online now, including CALVIN KLEIN Modern Cotton and the new CALVIN KLEIN Body ran

Ferring enters into worldwide OmniAb® platform license agreement with Ligand22.1.2018 14:00Pressemelding

Ferring Pharmaceuticals announced today that it has entered into a worldwide license agreement with Ligand Pharmaceuticals to use Ligand’s OmniAb platform® to discover new human monoclonal antibodies for a range of indications. Under the agreement, Ferring will use OmniAb to accelerate development solutions for unmet patient needs in reproductive medicine and women’s health, urology and gastroenterology. “Antibody-based therapies improve the quality of life and care for patients with a wide range of conditions but have not been fully investigated, in particular in the area of reproductive medicine and women’s health,” said Armin Metzger, Senior Vice President, Head of Global Pharmaceutical Research and Development, Ferring Pharmaceuticals. “This agreement expands Ferring’s growing capabilities in biologics and broadens our historical focus on peptides, opening up significant opportunities for discoveries that will help patients to live better lives.” Ligand's OmniAb® platforms produce

European Commission Approves ADCETRIS® (brentuximab vedotin) for CD30-Positive Cutaneous T-Cell Lymphoma after One Prior Systemic Therapy– Providing an Innovative Treatment Option to Patients22.1.2018 13:00Pressemelding

Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that the European Commission (EC) extended the current conditional marketing authorization of ADCETRIS® (brentuximab vedotin) and approved ADCETRIS for the treatment of adult patients with CD30-positive cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy. ADCETRIS is an antibody-drug conjugate (ADC) directed at CD30, which is expressed on skin lesions in approximately 50 percent of patients with CTCL. The decision follows a positive opinion from the Committee for Medicinal Products for Human Use (CHMP) on November 9, 2017. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005037/en/ “CTCL is a subtype of non-Hodgkin lymphoma that primarily involves the skin; it typically presents with red, scaly patches or thickened plaques of skin that often mimics eczema or psoriasis and can have a substantial impact on patients’ self-esteem. There a

Hilton Led Hospitality Industry in Customer Innovations and Recorded Best Ever Growth in 201722.1.2018 13:00Pressemelding

In 2017, Hilton (NYSE: HLT) achieved record-setting growth, unveiled industry-leading innovations, and introduced new benefits for guests and Team Members. This press release features multimedia. View the full release here: http://www.businesswire.com/news/home/20180122005292/en/ Hilton Led Hospitality Industry in Customer Innovations and Recorded Best Ever Growth in 2017 (Graphic: Business Wire) 2017 was a year of industry firsts, including the launch of Five Feet To Fitness, Hilton Honors loyalty program partnership with Amazon, Tapestry Collection by Hilton, and workplace innovations that received international recognition. It was also the year that Hilton introduced a ground-breaking concept – Connected Room – the first truly mobile-centric hotel room that will let guests personalize and control their stays from the award-winning Hilton Honors smartphone app. “Last year was another pioneering year for our team around the world, with the launch of new technologies, brands, and partn

Ingersoll Rand Announces Acquisition of ICS Group Holdings Limited, a Leading European Temperature Control and HVAC Solutions Provider22.1.2018 11:30Pressemelding

Ingersoll-Rand plc (NYSE:IR), a world leader in creating comfortable, sustainable and efficient environments, today announced the acquisition of United Kingdom-based ICS Group Holdings Limited (ICS Cool Energy). ICS Cool Energy will be part of the company’s Commercial Heating, Ventilation and Air Conditioning (HVAC) business. ICS Cool Energy is a privately owned temperature control and HVAC solutions and services company that specializes in temporary rental of energy efficient chillers for commercial and industrial buildings across Europe. It also sells, permanently installs and services high performance temperature control systems for all types of industrial processes. “ICS Cool Energy is a leader in the high margin rental services business with a reputation for strong customer service, helping building owners enhance productivity and reduce environmental impact,” said Dave Regnery, executive vice president of Ingersoll Rand. “This acquisition is a strong fit with our Trane business,

The Geneva Association: Insurance Industry Taking Action in Addressing Climate Change, Although External Hurdles Remain22.1.2018 10:00Pressemelding

The insurance industry is contributing significantly to building socio-economic resilience to climate change and supporting the transition to a low-carbon economy in their role as risk management experts and investors, although a number of challenges are hindering the industry’s efforts to scale up its contribution, according to a new research report from The Geneva Association, the leading international think tank of the insurance industry. The report ‘Climate Change and the Insurance Industry: Taking Action as Risk Managers and Investors’ is based on interviews with 62 C-level executives of globally active insurance and reinsurance companies, and offers insights into the role of the insurance industry in addressing climate change adaptation and mitigation. Anna Maria D’Hulster, Secretary General of The Geneva Association, commented: “The study has confirmed that climate change is a topic that has made its way up to the boardrooms of the insurance industry, although insurers are neith

I vårt presserom finner du alle våre siste saker, kontaktpersoner, bilder, dokumenter og annen relevant informasjon om oss.

Besøk vårt presserom